Coherus BioSciences shares are trading higher after the company announced FDA approval of UDENYCA ONBODY for pegfilgrastim-cbqv.
Portfolio Pulse from Benzinga Newsdesk
Coherus BioSciences' stock is trading higher following the announcement of FDA approval for UDENYCA ONBODY, a pegfilgrastim-cbqv product.
December 26, 2023 | 9:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coherus BioSciences' shares are experiencing an upswing due to the FDA's approval of their UDENYCA ONBODY product.
FDA approvals are significant milestones for biotech companies, often leading to increased investor confidence and potential revenue growth from the newly approved product. The approval of UDENYCA ONBODY is directly related to Coherus BioSciences and is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100